N calculation for trial about PK superiority [Power / Sample Size]

posted by dshah  – India, 2022-09-02 13:52 (979 d 23:12 ago) – Posting: # 23262
Views: 4,042

Hi Alex!

I am wondering why PK superiority? I am not getting if you do not prove faster onset of action with PD superiority, you can have advantage. Already the discussion for Tmax assessment (EMA PSG) is discussed in forum. Could you provide more details for not focusing on PD superiority?
Regards,
Divyen Shah

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,669 registered users;
123 visitors (0 registered, 123 guests [including 11 identified bots]).
Forum time: 13:05 CEST (Europe/Vienna)

Freedom is always and exclusively
freedom for the one
who thinks differently.    Rosa Luxemburg

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5